CompaniesGSNO Therapeutics

GSNO Therapeutics

active

Shelton, WA, United States

Founded 2021

About

GSNOR Inhibitors

Areas of Focus

Categories

Small Molecule PharmaceuticalSeattle/Pacific Northwest

Clinical Trials (1)

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

108

By Phase

PHASE2: 1

By Status

UNKNOWN: 1

Clinical Trials Pipeline1 trial

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2020

2021

2022

2023

Today

Hover over trial bars to see details

Recent Trials

NCT04600778Lead Sponsor

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

108 participants

Started: Feb 3, 2021 · Completed: Apr 30, 2022

Locations (1)

Headquarters

Shelton, WA, United States

Map

Loading map...